ES523039A0 - "un procedimiento para la preparacion de derivados del indol" - Google Patents

"un procedimiento para la preparacion de derivados del indol"

Info

Publication number
ES523039A0
ES523039A0 ES523039A ES523039A ES523039A0 ES 523039 A0 ES523039 A0 ES 523039A0 ES 523039 A ES523039 A ES 523039A ES 523039 A ES523039 A ES 523039A ES 523039 A0 ES523039 A0 ES 523039A0
Authority
ES
Spain
Prior art keywords
indol
derivatives
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES523039A
Other languages
English (en)
Spanish (es)
Other versions
ES8407473A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10530876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES523039(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ES8407473A1 publication Critical patent/ES8407473A1/es
Publication of ES523039A0 publication Critical patent/ES523039A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
ES523039A 1982-06-07 1983-06-07 "un procedimiento para la preparacion de derivados del indol" Granted ES523039A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8216526 1982-06-07

Publications (2)

Publication Number Publication Date
ES8407473A1 ES8407473A1 (es) 1984-10-01
ES523039A0 true ES523039A0 (es) 1984-10-01

Family

ID=10530876

Family Applications (3)

Application Number Title Priority Date Filing Date
ES523039A Granted ES523039A0 (es) 1982-06-07 1983-06-07 "un procedimiento para la preparacion de derivados del indol"
ES529802A Expired ES8601880A1 (es) 1982-06-07 1984-02-16 Un procedimiento para la preparacion de derivados del indol
ES544281A Expired ES8609247A1 (es) 1982-06-07 1985-06-17 Un procedimiento para la preparacion de derivados del indol

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES529802A Expired ES8601880A1 (es) 1982-06-07 1984-02-16 Un procedimiento para la preparacion de derivados del indol
ES544281A Expired ES8609247A1 (es) 1982-06-07 1985-06-17 Un procedimiento para la preparacion de derivados del indol

Country Status (33)

Country Link
US (1) US4816470A (enExample)
JP (1) JPS5942366A (enExample)
KR (1) KR900006681B1 (enExample)
AT (1) AT381933B (enExample)
AU (1) AU566149B2 (enExample)
BE (1) BE896986A (enExample)
CA (1) CA1199643A (enExample)
CH (1) CH657359A5 (enExample)
CY (1) CY1458A (enExample)
CZ (1) CZ280529B6 (enExample)
DE (2) DE3320521A1 (enExample)
DK (1) DK260183D0 (enExample)
DO (1) DOP1989476000A (enExample)
ES (3) ES523039A0 (enExample)
FI (1) FI79530C (enExample)
FR (1) FR2530625B1 (enExample)
GB (1) GB2124210B (enExample)
GR (1) GR79215B (enExample)
HK (1) HK14789A (enExample)
IE (1) IE55358B1 (enExample)
IL (1) IL68913A (enExample)
IT (1) IT1170387B (enExample)
KE (1) KE3833A (enExample)
LU (1) LU84852A1 (enExample)
MX (1) MX9202623A (enExample)
MY (1) MY8700179A (enExample)
NL (1) NL193694C (enExample)
NZ (1) NZ204482A (enExample)
PH (1) PH19908A (enExample)
PT (1) PT76830B (enExample)
SE (1) SE452459B (enExample)
SK (1) SK404091A3 (enExample)
ZA (1) ZA834110B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8332434D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Production of chemical compounds
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
US5270333A (en) * 1986-01-28 1993-12-14 Glaxo Group Limited Indole derivatives
GB8601959D0 (en) * 1986-01-28 1986-03-05 Glaxo Group Ltd Indole derivatives
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
US4997841A (en) * 1987-08-13 1991-03-05 Glaxo Group Limited Indole derivatives
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
HUT57185A (en) * 1990-03-21 1991-11-28 Merrell Dow Pharma Process for producing 8-sulfamil-methylen-2-amino-tetraline derivatives and pharmaceutical compositions containing them
US5935925A (en) * 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5155218A (en) 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
GB9013845D0 (en) * 1990-06-21 1990-08-15 Glaxo Group Ltd Process
US5077293A (en) * 1990-06-29 1991-12-31 Bristol-Myers Squibb Co. 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9103770D0 (en) * 1991-02-22 1991-04-10 Glaxo Group Ltd Chemical compounds
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
CA2084531A1 (en) 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211276D0 (en) * 1992-05-28 1992-07-15 Glaxo Lab Sa Pharmaceutical compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
ES2055651B1 (es) * 1992-07-20 1995-03-01 Vita Invest Sa Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
RU2108326C1 (ru) * 1993-02-26 1998-04-10 Вита-Инвест С.А. Способ получения 2-карбокси-3-[2-(диметиламино)этил]-n-метил-1h-индол-5-метансульфонамида или его сложных эфиров
US5382592A (en) * 1993-09-16 1995-01-17 Bristol-Myers Squibb Company Antimigraine cyclobutenedione derivatives of tryptamines
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
FR2731224B1 (fr) * 1995-03-02 1997-05-30 Pf Medicament Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6416472B1 (en) 1997-11-06 2002-07-09 Edus Inc. Method and device for measuring cognitive efficiency
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20020099059A1 (en) * 2000-08-23 2002-07-25 Joel Saper Combination therapy for the treatment of migraine
JP4959907B2 (ja) * 2001-03-27 2012-06-27 ワーナー チルコット（アイルランド）リミティド 抗菌剤投与のための膣内用ドラッグデリバリーデバイス
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2003105836A1 (en) * 2002-06-13 2003-12-24 Dr. Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-N-methyl-1H-indole-5-methanesulfonamide and the Succinate Thereof
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
WO2004056769A2 (en) 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
ATE546134T1 (de) 2002-12-26 2012-03-15 Pozen Inc Mehrschichtige dosierformen enthaltend naproxen und triptane
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
EP1708684A2 (en) * 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
KR20120106757A (ko) * 2003-09-26 2012-09-26 알자 코포레이션 오피오이드 및 비오피오이드 진통제의 제어 방출 제제
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CA2605073C (en) * 2005-04-13 2017-12-12 Neuraxon, Inc. Substituted indole compounds having nos inhibitory activity
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
ZA200809659B (en) * 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
US20080103189A1 (en) * 2006-10-19 2008-05-01 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted indoles
MX2010005343A (es) * 2007-11-16 2010-08-09 Neuraxon Inc Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
JP2011503120A (ja) * 2007-11-16 2011-01-27 ニューラクソン，インコーポレーテッド 内臓痛を治療するためのインドール化合物および方法
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
AU2009253738B2 (en) 2008-05-27 2012-12-13 Biota Scientific Management Pty Ltd Antiviral salts
WO2009152551A1 (en) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Pharmaceutical formulation
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
MX338110B (es) 2009-09-25 2016-04-01 Reddys Lab Ltd Dr Formulaciones que comprenden compuestos de triptano.
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
HK1248564A1 (zh) 2015-03-02 2018-10-19 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10537554B2 (en) 2015-08-05 2020-01-21 Upsher-Smith Laboratories, Llc Pharmaceutical composition for treating migraine
WO2017130141A1 (en) 2016-01-27 2017-08-03 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
NZ197998A (en) * 1980-08-12 1985-08-16 Glaxo Group Ltd 5-amino(methyl)-1h-indol-3-ylalkaneamines
DK157920C (da) * 1980-08-12 1990-08-06 Glaxo Group Ltd Analogifremgangsmaade til fremstilling af indolderivater
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GB2082175B (en) * 1980-08-12 1984-05-02 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
FI79530B (fi) 1989-09-29
BE896986A (fr) 1983-12-07
JPH0329069B2 (enExample) 1991-04-23
ES8407473A1 (es) 1984-10-01
CZ404091A3 (en) 1993-04-14
IE831335L (en) 1983-12-07
SE452459B (sv) 1987-11-30
AU566149B2 (en) 1987-10-08
US4816470A (en) 1989-03-28
DOP1989476000A (es) 1996-02-03
SE8303208L (sv) 1983-12-08
NL8302031A (nl) 1984-01-02
MY8700179A (en) 1987-12-31
DE19375045I2 (de) 2002-09-05
PH19908A (en) 1986-08-13
DE3320521A1 (de) 1983-12-08
ES529802A0 (es) 1985-11-16
AU1544183A (en) 1983-12-15
ES8601880A1 (es) 1985-11-16
SK277877B6 (en) 1995-06-07
NL193694B (nl) 2000-03-01
IL68913A (en) 1987-08-31
IL68913A0 (en) 1983-10-31
PT76830A (en) 1983-07-01
GB8315564D0 (en) 1983-07-13
ES8609247A1 (es) 1986-07-16
CY1458A (en) 1989-07-21
KR900006681B1 (ko) 1990-09-17
IT8348422A0 (it) 1983-06-03
JPS5942366A (ja) 1984-03-08
GR79215B (enExample) 1984-10-22
DK260183D0 (da) 1983-06-06
ATA208483A (de) 1986-05-15
KR840005095A (ko) 1984-11-03
DE3320521C2 (enExample) 1992-06-25
IT1170387B (it) 1987-06-03
FI832035L (fi) 1983-12-08
ES544281A0 (es) 1986-07-16
GB2124210B (en) 1985-11-13
GB2124210A (en) 1984-02-15
HK14789A (en) 1989-02-24
NZ204482A (en) 1986-09-10
MX9202623A (es) 1992-06-30
CA1199643A (en) 1986-01-21
CH657359A5 (fr) 1986-08-29
LU84852A1 (fr) 1985-03-29
KE3833A (en) 1988-11-18
ZA834110B (en) 1985-01-30
CZ280529B6 (cs) 1996-02-14
FI79530C (fi) 1990-01-10
FI832035A0 (fi) 1983-06-07
PT76830B (en) 1986-04-21
AT381933B (de) 1986-12-10
SE8303208D0 (sv) 1983-06-07
FR2530625A1 (fr) 1984-01-27
NL193694C (nl) 2000-07-04
IE55358B1 (en) 1990-08-29
SK404091A3 (en) 1995-06-07
FR2530625B1 (fr) 1986-04-18

Similar Documents

Publication Publication Date Title
ES523039A0 (es) "un procedimiento para la preparacion de derivados del indol"
ES522447A0 (es) Procedimiento para la preparacion de 1,4-diceto-pirrollo-3,4-c-pirroles
ES546631A0 (es) Un procedimiento para la preparacion de derivados de indol
ES511498A0 (es) Un procedimiento para la preparacion de derivados del 1,2,5-tiadiazol
ES526295A0 (es) Un procedimiento para la preparacion de derivados de 1-normon-2-ilo
ES531659A0 (es) Un procedimiento para la preparacion de nuevos derivados de arilamida
ES535980A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina
ES522886A0 (es) "procedimiento para la preparacion de derivados de 1-sulfo-2-oxoacetidina"
AR241017A1 (es) "procedimiento para la preparacion de fenilsilfoniloxibencimidazolcarbamatos sustituidos".
ES531562A0 (es) Un procedimiento para la preparacion de derivados de azetidina
ES544290A0 (es) Un procedimiento para la preparacion de derivados del indano
ES524399A0 (es) Un procedimiento para la preparacion de derivados de milbenicina d
ES530668A0 (es) Un procedimiento para la preparacion de nuevos derivados de fosfolipidos
ES524154A0 (es) Procedimiento para la preparacion de n-arilsulfonil-n'-triazolureas
ES511834A0 (es) "procedimiento para la preparacion de nuevas indolinonas".
ES508811A0 (es) "prodedimiento para la preparacion de derivados de fenoxi-aminipropanol"
ES508293A0 (es) "procedimiento para la preparacion de derivados de tiazolina".
ES540341A0 (es) Un procedimiento para la preparacion de derivados de piperi-dina
ES530388A0 (es) Procedimiento para preparar derivados del 2-azabiciclo-2.2.1-heptano.
ES527804A0 (es) Un procedimiento para la preparacion de derivados de oxacefalosporina
ES508152A0 (es) "un procedimiento para la preparacion de nuevos derivados de oxodiazolopirimidina".
AR240934A1 (es) Procedimiento para obtener derivados de acridanona"
ES526569A0 (es) Procedimiento para la preparacion de alcanolaminoxi-derivados de la 3,4-dihidro-2h-1,4-benzotiazin-3-ona
ES508723A0 (es) "un procedimiento para la preparacion de derivados de metoxicefalosporinas".
ES522884A0 (es) "un procedimiento para la preparacion de derivados de hidroxiimino y alcoxiimino de 1,4-dihidropiridina"